CogniBen®

A patented, synergistic blend of ingredients that support: Optimal Cognitive Function* Increased Concentration, Focus and Energy* Restoration of Mental Alertness* Documented Safety, Tolerability and Efficacy in Human Subjects A recent single-blind, dose titration, outpatient study evaluated the efficacy of Cogniben® in 10 adults (18 to 55 years) with symptoms of cognitive impairment. Subjects were titrated from half tablet of Cogniben® daily, up to the maximal allowed dose of two tablets per day by the end of the 2nd week. This dose was maintained for an additional 5 weeks. Subjects’ symptoms, well-being, and improvements were assessed via questionnaires at baseline and subsequent visits. The primary efficacy endpoint was the average change from baseline to endpoint in total average symptom score. Supported by proven clinical efficacy in adults with symptoms of cognitive impairment. Learn more about the synergistic blend of ingredients and the study results. *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. * Patent number: US 10,159,702